CoChat
Sign Up
Cited by 103Bipolar Disorder and TreatmentSchizophrenia research and treatmentPersonality Disorders and Psychopathology

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials

Open access
Vázquez, Gustavo H., Holtzman, Jessica N., Lolich, María, Ketter, Terence A., Baldessarini, Ross J.·2015·European Neuropsychopharmacology
DOI 10.1016/j.euroneuro.2015.07.013
Open this paper in CoChat — free accountOpen PDF

Abstract

Bipolar disorder (BD) is a recurrent, lifelong illness with high risks of disability and excess mortality. Despite many treatment options with demonstrated short-term efficacy, evidence concerning long-term treatment effectiveness in BD remains limited and the relative value of naturalistic studies versus randomized, controlled trials (RCTs) in its assessment, uncertain. Systematic computer-searching yielded 10 naturalistic studies and 15 RCTs suitable for analysis of recurrence rates and their association with treatments and selected clinical factors. In naturalistic studies (3904 BD subjects, 53.3% women, 85.8% BD-I, mean onset age 29.1, followed up to 2.1 years), the pooled recurrence rate was 55.2% (26.3%/year). In RCTs (4828 subjects, 50.9% women, 96.0% BD-I, mean onset age 23.1, followed up to 1.9 years), the pooled recurrence rate was 39.3% (21.9%/year) with mood-stabilizing drug-treatment versus 60.6% (31.3%/year) with placebo; drug-versus-placebo outcomes favored antipsychotics over lithium, and disfavor an approved anticonvulsant. Depressive episode-polarity increased from 27.7% at intake to 52.0% at first-recurrence (p<0.0001). Recurrence rate (%/year) did not differ by study-type, was greater with younger onset and rapid-cycling, and paradoxically declined with longer observation. In short, recurrences of major affective episodes up to two years during putative mood-stabilizing treatment of BD patients in prospective, naturalistic studies and RCTs were substantial and similar (26.3 vs. 21.9%/year). Episode-polarity shifted strongly toward depressive first-recurrences. These findings support the value of naturalistic studies to complement long-term RCTs, and add to indications that control of depression in BD remains particularly unsatisfactory.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2015.07.013

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 103

Related

See all

Metadata

Authors
Vázquez, G. H., Holtzman, J. N., Lolich, M., Ketter, T. A., & Baldessarini, R. J.
Affiliations
  • McLean Hospital (US)
  • Stanford Medicine (US)
  • University of Palermo (AR)
  • Harvard University (US)
Corresponding author
Vázquez, Gustavo H.
ORCID
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2015-10
Volume
25
Issue
10
Pages
1501-1512
ISSN
0924-977X (ISSN-L)
DOI
10.1016/j.euroneuro.2015.07.013
OpenAlex
W1960912647
Cited by
102
References
53
Citations by year
2026: 7 · 2025: 12 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 11 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 15 · 2016: 4
FWCI
7.30
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-nd)
Funders
  • Bruce J. Anderson Foundation
  • McLean Private Donors Research Fund (RJB)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
bipolar disorder, recurrence rate, naturalistic study, randomized controlled trials, mood stabilizers, lithium, antipsychotic drugs, antiepileptic drugs, rapid cycling bipolar disorder, age of onset, long-term treatment effectiveness
MeSH terms
Bipolar Disorder, Humans, Recurrence, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review